Drug being studied at Butler Hospital could play a significant role in treating Alzheimer’s disease
PROVIDENCE, R.I. (WLNE) – A drug is currently being studied at both Butler and Rhode Island Hospitals that could be a game changer when it comes to treating Alzheimer’s disease.
The drug has been submitted to the FDA for approval, and if approved it would become the first therapy to reduce the clinical decline of Alzheimer’s disease in patients.
Dr. Stephen Salloway of Butler Hospital said, “This study was based on people with early Alzheimer’s so they had mild memory loss or mild dementia, and they were at risk of developing more serious memory loss, and more disability. And the whole goal of this medicine is to slow down the disease progression, so people can have quality life for as long as possible.”
ABC 6 News was told that both Butler and Rhode Island Hospitals have the most patients in the world currently involved in this study.